Aims: Aim of this study was to evaluate the toxicity profile and locoregional response rate comparing hypofractionated chemoradiation with conventional chemoradiation.

Materials and Methodology: We conducted a prospective study done in 59 untreated patients of squamous cell carcinoma of cervix (FIGO stage II –IVA) with histologically confirmed diagnosis and no evidence of distant metastasis. They were randomized to Arm A (HRT) and Arm B (CRT), 29 patients in arm A and 30 patients in arm B. Arm A received EBRT 39Gy in 13#, while Arm B received 46Gy in 23# with standard pelvic field box technique. Both arm received concurrent cisplatin 100mg/m2 three weekly. EBRT was followed by 3 sessions of Intracavitory Brachytherepy (ICBT) at a week interval to a dose of 7Gy per session to point A by HDR. End point of the study were tumor response, acute (3 months) and late toxicities (1 year).

Results: 29 patients in Arm A and 30 patients in Arm B were recruited over 18 months. All patients completed minimum follow up of 1 year. 26 patients completed treatment in Arm A and 26 patients completed treatment in Arm B. Maximum acute toxicity in Arm A in term of skin reaction was grade I (57.6%) and proctitis is grade I (64.3%) with median time for completion of treatment 7-8 weeks. Maximum acute toxicity in Arm B in skin reaction was grade I (73%) and proctitis grade I (53.4%) with median time for completion of treatment 7-8 weeks. Complete response at 3 months is 100% in arm A and 92.3% in arm B. Overall Survival at 6 months was 80.7% equivalent in both arms. Progression free survival at 6 months was 65.3% and 76.9% in arm A and arm B respectively.

Conclusion: Tumor response in patients treated with hypofractionated radiotherapy appears comparable to that of standard fractionation with manageable toxicity profile.

Keywords: Cancer; Tumour Control Probability (TCP); Toxicity

References

1. GLOBOCON 2018 Data source: Global x cancer observatory (http://gco.iarc.fr/) International Agency for Research on cancer (2019).
2. Eifel PJ., et al. “Gynecologic cancers: Cancer of cervix, vagina, and vulva”. In: Devita VT, Theodore SL, Sleven AR, editors. DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 8^th, h. 42, Sec. 2. Philadelphia: Lippincott Williams and Wilkins; 2008 Lancet 359.9312 (2002): 1093-1101.
3. NCI Press Office NCI Issues Clinical Announcement on Cervical Cancer: Chemotherapy plus Radiation Improves Survival (1999).
4. Huang Z., et al. “Onset Time of Tumor Repopulation for Cervical Cancer: First Evidence from Clinical Data”. International Journal of Radiation Oncology, Biology, Physics 84 (2012): 478-484.
5. Tsang RW., et al. “Proliferation measurements with flow cytometry T-pot in cancer of the uterinecervix: Correlation between laboratories and preliminary clinical results”. International Journal of Radiation Oncology, Biology, Physics 5 (1995): 1319-1321.
6. Hall E and Giaccia AJ. “Radiobiology for the Radiologist”. Lippincott William and Wilkins, Philadelphia, seventh Edition (2012): 403.
7. Sridevi Aswathy., et al. International Journal of Women's Health 7 (2015): 405-414. PMCID: PMC4404964.
8. Muñoz N., et al. “International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group”. Lancet 9312 (2002): 1093-1101.
9. Huang Z., et al. “Onset Time of Tumor Repopulation for Cervical Cancer: First Evidence from Clinical Data”. International Journal of Radiation Oncology, Biology, Physics 84 (2012): 478-484.
10. Muckaden Mary A., et al. “Hypofractionated Radiotherapy in Carcinoma Cervix IIIB--Tata MemorialHospital Experience”. Indian Journal of Cancer4 (2002): 127-134.
11. Swaroop VS and Gostout CJ. “Endoscopic treatment of chronic radiation proctopathy”. Journal of Clinical Gastroenterology1 (1998): 36-40.
12. Yegappan M., et al. “The surgical management of colorectal complications from irradiation for carcinoma of the cervix”. Annals-Academy of Medicine Singapore 27 (1998): 627-630.

Citation

Citation: Pramod Kumar Singh.,et al. “A Randomized Study to Compare the Outcome and Tolerability of Hypofractionated Chemoradiotherapy Versus Conventional Chemoradiotherapy in Advance Carcinoma of Cervix”.Acta Scientific Cancer Biology 8.2 (2024): 02-07.

Copyright

Copyright: © 2024 Pramod Kumar Singh.,et al. “Study of p16INK4a Immunostaining as Specific Biomarker in the diagnosis of Cervical Intraepithelial Neoplasia and This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.